Evommune, Inc. EVMN
7.24 USD +0.36 (+5.23%)
Regular-session close
7.37 +0.13 +1.81%
Pre-market · Nov 20, 4:00 AM ET
6.92 Day range 7.39
4.94 52-week range 33.20
- YTD
- -57.71%
- 1 year
- -62.47%
Benzinga news
benzinga.com Needham Maintains Buy on Evommune, Lowers Price Target to $25 Needham analyst Serge Belanger maintains Evommune (NYSE:EVMN) with a Buy and lowers the price target from $28 to $25.
benzinga.com Evommune Q3 EPS $(0.85) Misses $(0.84) Estimate Evommune (NYSE:EVMN) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.84) by 1.19 percent. This is a 89.47 percent increase over losses of $(8.07) per…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…benzinga.com Evommune Receives Exclusive License From Hinova Pharmaceuticals To Develop, Manufacture, Commercialize EVO570 Outside China; Hinova To Get $30M Upfront Payment Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, and Hinova Pharmaceuticals Inc. (SSE: 688302)
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
